Portail Grand Angle

[1] Estimations nationales de l’incidence et de la mortalité par cancer en France mé­tropolitaine entre 1990 et 2018. Volume 1 – Tumeurs solides. Santé publique France 2019

[2] Farges O et al. The Theory and Practice of Pancreatic Surgery in France. Ann Surg. nov 2017;266(5):797­804.

[3] Ferlay J et al. More deaths from pancreatic cancer than breast cancer in the EU by2017. Acta Oncol Stockh Swed. oct 2016;55(9­10):1158­60.

[4] Sharon CE et al. Fourteen years of pancreatic surgery for malignancy among ACS­NSQIP centers: Trends in major morbidity and mortality. Surgery. 7 mai 2022; https://doi.org/10.1016/j.surg.2022.03.030

[5] Sánchez ­Velázquez P et al. Benchmarks in Pancreatic Surgery:A Novel Tool for Unbiased Outcome Comparisons. Ann Surg. août 2019;270(2):211­8.

[6] Raptis DA et al. Defining Benchmark Outcomes for Pancreatoduodenectomy With Portomesenteric Venous Resection. Ann Surg. nov 2020;272(5):731­7.

[7] Russell TB et al. Procedure ­specific morbidity of pancreatoduodenectomy: a sys­tematic review of incidence and risk factors. ANZ J Surg. juin2022;92(6):1347­55.

[8] Thomas AS et al. Prevalence and Risk Factors for Pancreatic Insufficiency After Partial Pancreatectomy. J Gastrointest Surg [Internet]. 22 mars 2022 https://doi.org/10.1007/s11605-­022-­05302-­3

[9] De Bruijn KMJ et al. New ­onset diabetes after distal pancreatectomy: a systema­tic review. Ann Surg. mai 2015;261(5):854­61.

[10] Roeyen G et al. Expert opinion on management of pancreatic exocrine insuffi­ciency in pancreatic cancer. ESMO Open. févr 2022;7(1):100386.

[11] Rahib L, et al. Estimated Projection of US Cancer Incidence and Death to 2040. JAMA Netw Open. 1 avr 2021;4(4):e214708.

[12] Bouvier AM et al. Focus on an unusual rise in pancreatic cancer incidence in France. Int J Epidemiol. 1 déc 2017;46(6):1764­72.

[13] Mizrahi JD et al. Pancreatic cancer. Lancet Lond Engl. 27 juin 2020;395(10242): 2008­20.

[14] Bengtsson A et al. The actual 5 ­year survivors of pancreatic ductal adenocar­cinoma based on real­world data. Sci Rep. 02 2020;10(1):16425.

[15] Schmidt CM et al. Acinar Cell Carcinoma of the Pancreasin the United States: Prognostic Factors and Comparison to Ductal Adenocarcinoma. J GastrointestSurg. 3 oct 2008;12(12):2078.

[16] DeMartel C et al. Epidémiologie du cancer du pancréas. I. In: Cancer du Pancréas. Arnette; 2010. p. 12­30. (Monographies de l’AFC).

[17] Scott AT et al. Evaluation and Management of Neuroendocrine Tumors of the Pancreas. Surg Clin North Am. août 2019;99(4):793­814.

[18] Souche R et al. Surgical Management of Neuroendocrine Tumours of the Pancreas. J Clin Med. sept 2020;9(9):2993.

[19] Vaghaiwalla T et al. Surgical Management of Pancreatic Neuroendocrine Tu­ mors. Surg Oncol Clin N Am. avr 2020;29(2):243­52.

[20] Teo RYA, et al. Systematic review of current prognostication systems for pancreatic neuroendocrine neoplasms. Surgery. 1 avr 2019;165(4):672­85.

[21] de Ponthaud C et al. Updated Principles of Surgical Management of Pancreatic Neuroendocrine Tumours (pNETs):What Every SurgeonNeeds to Know. Cancers. 27 nov 2021;13(23):5969.

[22] Belfiori G et al. Vascular resection during pancreatectomy for pancreatic headcancer: A technical issue or a prognostic sign? Surgery. févr 2021;169(2):403­10.

[23] Al­ Hawary MM et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the ameri­ can pancreatic association. Gastroenterology. janv 2014;146(1):291­304.e1.

[24] Marion­ Audibert AM et al. Routine MRI With DWI Sequences to Detect Liver Metastases in Patients With Potentially Resectable Pancreatic Ductal Carcinoma and Normal Liver CT: A Prospective Multicenter Study. AJR Am J Roentgenol. nov 2018;211(5):W217­25.

[25] Raman SP et al . Cross­sectional imaging and the role of positron emission tomo­graphy in pancreatic cancer evaluation. Semin Oncol. févr 2015;42(1):40­58.

[26] Glant JA et al. Does the interval from imaging to operation affect the rate of unanticipated metastasis encountered during operation for pancreatic adenocar­ cinoma? Surgery. oct2011;150(4):607­16.

[27] Raman SP et al. Impact of the time interval between MDCT imaging and surgery on the accuracy of identifying metastatic disease in patients with pancreatic cancer.AJR Am J Roentgenol. janv 2015;204(1):W37­42.

[28] Neuzillet C et al. Pancreatic cancer: French clinical practice guidelines for dia­gnosis, treatment and follow­up. Dig LiverDis. déc 2018;50(12):1257­71.

[29] De Angelis C et al. Endoscopic ultrasonography for pancreatic cancer: current and future perspectives. J Gastrointest Oncol. juin 2013;4(2):220­30.

[30] Suto H et al. Prediction of local tumor control and recurrence ­free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiotherapy. J Surg Oncol. 15 mars 2022.

[31] Tabata K et al. Prediction of pathological response to preoperative chemothe­rapy for pancreatic ductal adenocarcinoma using 2­-[18F]­-fluoro­-2­-deoxy­-d­-glucose positron­-emission tomography. Clin Radiol. juin 2022;77(6):436­42.

[32] McGahan W et al. High SUVmax on routine pre­operative FDG­PET predicts early recurrence in pancreatic and peri­ampullary cancer. HPB. 30 janv 2022;S1365­182X(22)00038­7.

[33] Ito T et al. clinical practice guidelines for gastroenteropancreatic neuroen­docrine neoplasms: diagnosis, treatment, and follow­up: a synopsis ­ JNETS 2021; 56:1033­44

[34] Gupta V et al. Organ preserving pancreatic resections offer better long-­term conservation of pancreatic function at the expense of high perioperative major mor­bidity: a fair trade-­off for benign or low malignant potential pancreatic neoplasms — a single-­center experience. Langenbecks Arch Surg 2022 doi: 10.1007/s00423­022­ 02491­y

[35] Asano Y et al. Clinical outcomes of organ ­preserving pancreatectomy for benign or low­grade malignant pancreatic tumors: A multicenter nationwide survey in Japan. J Hepato­Biliary­Pancreat Sci. 19 avr 2022

[36] Bassi C et al. Value of regional lymphadenectomy in pancreatic cancer. HPB. juin 2005;7(2):87­92.

[37] Tol JAMG et al. Definition of a standard lymphadenectomy in surgery forpancreatic ductal adenocarcinoma: A consensus statement by the International Stu­dy Group on Pancreatic Surgery (ISGPS). Surgery. sept 2014;156(3):591­600.

[38] Kotb A et al. Meta-­analysis and trial sequential analysis of randomised controlled trials comparing standard versus extended lymphadenectomy in pancreatoduode­nectomy for adenocarcinoma of the head of pancreas. Langenbecks Arch Surg. mai 2021;406(3):547­61.

[39] Orci LA et al. A meta­-analysis of extended versus standard lymphadenectomy in patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma. HPB. juill 2015;17(7):565­72.

[40] Klaiber U et al. Randomized Trial of Pylorus ­Preserving vs. Pylorus ­Resecting Pancreatoduodenectomy: Long­Term Morbidity and Quality of Life. J Gastrointest Surg. févr 2020;24(2):341­52.

[41] Hackert T et al. Pylorus Resection Does Not Reduce Delayed Gastric Emptying After Partial Pancreatoduodenectomy: A Blinded Randomized Controlled Trial (PRO­ PP Study, DRKS00004191). Ann Surg. juin 2018;267(6):1021­7.

[42] Klaiber U et al. Meta-­analysis of delayed gastric emptying after pylorus ­pre­ serving versus pylorus­resecting pancreatoduodenectomy. Br J Surg. 28 févr 2018; 105(4):339­49.

[43] de Rooij T et al. Minimally Invasive Versus Open Distal Pancreatectomy (LEO­ PARD): A Multicenter Patient ­blinded Randomized Controlled Trial. Ann Surg. janv2019;269(1):2­9.

[44] Chowdappa R et al. Modified Heidelberg technique of pancreatic anastomosis postpancreaticoduodenectomy 10 years of experience. South Asian J Cancer. juin2019;8(2):88­91.

[45] Hirono S et al. Modified Blumgart Mattress Suture Versus Conventional Inter­rupted Suture in Pancreaticojejunostomy During Pancreaticoduodenectomy: Rando­mized Controlled Trial. Ann Surg. févr 2019;269(2):243­51.

[46] Clemente Getal. Pancreatico­Jejunostomy On Isolated Loop After Pancreati­co­Duodenectomy: Is It Worthwhile? J Gastrointest Surg Off J Soc Surg Aliment Tract. juin 2022;26(6):1205­12.

[47] Shrikhande SV et al. Pancreatic anastomosis after pancreatoduodenectomy: A position statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. mai 2017;161(5):1221­34.

[48] Kilambi R et al. Duct-­to­-mucosa versus dunking techniques of pancreaticoje­ junostomy after pancreaticoduodenectomy: Do we need more trials? A systematic review and meta­analysis with trial sequential analysis ­ J surg oncol https://doi.org/10.1002/jso.24986

[49] Hai H et al. Duct­-to­-mucosa versus other types of pancreaticojejunostomy for the prevention of postoperative pancreatic fistula following pancreaticoduodenec­tomy. Cochrane Database Syst Rev. 15 mars 2022;3:CD013462.

[50] Hüttner FJ et al. Antecolic versus retrocolic reconstruction after partial pancrea­ticoduodenectomy. Cochrane Database Syst Rev. 11 janv 2022;1:CD011862.

[51] van Hilst J et al. Minimally Invasive versus Open Distal Pancreatectomy for Duc­tal Adenocarcinoma (DIPLOMA): A Pan­European Propensity Score Matched Study.Ann Surg. janv 2019;269(1):10­7.

[52] Hang K et al. Splenic vessels preserving versus Warshaw technique in spleenpreserving distal pancreatectomy: A systematic review and meta­analysis. Int J Surg Lond Engl. juill 2022;103:106686.

[53] Kimura W et al. Spleen­ preserving distal pancreatectomy with conservation ofthe splenic artery and vein. Surgery. nov 1996;120(5):885­90.

[54] Warshaw AL. Conservation of the spleen with distal pancreatectomy. Arch Surg Chic Ill 1960. mai 1988;123(5):550­3.

[55] Korrel M et al. Short­-Term Outcomes After Spleen­ Preserving Minimally Invasive Distal Pancreatectomy With or Without Preservation of Splenic Vessels: A Pan­Euro­pean Retrospective Study in High­Volume Centers. Ann Surg. 2 juin 2021.

[56] Miao Y et al. Management of the pancreatic transection plane after left (distal)pancreatectomy: Expert consensus guidelines by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. juill 2020;168(1):72­84.

[57] Strasberg SM et al. Radical antegrade modular pancreatosplenectomy. Surgery. mai 2003;133(5):521­7.

[58] Strasberg SM et al. Radical antegrade modular pancreatosplenectomy proce­dure for adenocarcinoma of the body and tail of the pancreas: ability to obtain nega­tive tangential margins. J Am Coll Surg. févr 2007;204(2):244­9.

[59] Nießen A et al. State­of­the­art surgery for pancreatic cancer. Langenbecks Arch Surg. mars 2022;407(2):443­50.

[60] Heidt DG et al. Total pancreatectomy: indications, operative technique, andpostoperative sequelae. J Gastrointest Surg Off J Soc Surg Aliment Tract. févr 2007;11(2):209­16.

[61] Aleotti F et al. Total pancreatectomy sequelae and quality of life: results ofislet autotransplantation as a possible mitigation strategy. Updat Surg. août 2021; 73(4):1237­46.

[62] Gilliland TM et al. Nutritional and Metabolic Derangements in Pancreatic Cancer and Pancreatic Resection. Nutrients. 7 mars 2017;9(3):E243.

[63] Alexandre P. Haute Autorité de santé. 2019;25.

[64] Strobel O et al. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. janv 2019;16(1):11­26.

[65] Marchegiani G et al. Post pancreatectomy Acute Pancreatitis (PPAP): Definitionand Grading From the International Study Group for Pancreatic Surgery (ISGPS). Ann Surg. 1 avr 2022;275(4):663­72.

[66] Wente MN et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. nov 2007;142(5):761­8.

[67] Wente MN et al. Post pancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery. juill 2007;142(1):20­5.

[68] Bassi C et al. Postoperative pancreatic fistula: an international study group (IS­GPF) definition. Surgery. juill 2005;138(1):8­13.

[69] Besselink MG et al. Definition and classification of chyle leak after pancreatic operation: A consensus statement by the International Study Group on Pancreatic Surgery. Surgery. févr 2017;161(2):365­72.

[70] Bassi C et al. The 2016 update of the International Study Group (ISGPS) defi­nition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. mars2017;161(3):584­91.

[71] Duarte Garcés AA et al. Reappraisal of post­pancreatectomy hemorrhage (PPH) classifications: do we need to redefinegrades A and B? HPB. août2018;20(8):702­7.

[72] Eisenberg JD et al. Delayed Gastric Emptying After Pancreaticoduodenectomy: an Analysis of Risk Factors and Cost. J Gastrointest Surg Off J Soc Surg Aliment Tract. sept 2015;19(9):1572­80.

[73] Fahlbusch T et al. Impact of pylorus preservation on delayed gastricemptying after pancreaticoduodenectomy­-analysis of 5,000 patients based on the German StuDoQ|Pancreas­Registry. Gland Surg. janv 2022;11(1):67­76.

[74] Muzzolini M et al. Incidence and risk factors for Chyle leak after pancreatic sur­gery for cancer: A comprehensive systematic review. Eur J Surg Oncol. avr 2022;48(4):707­17.

[75] Stoop TF et al. Impact of Endocrine and Exocrine Insufficiency on Quality of Life After Total Pancreatectomy. Ann Surg Oncol. févr 2020;27(2):587­96.

[76] Sabater L et al. Evidence­-based Guidelines for the Management of Exocrine Pancreatic Insufficiency After Pancreatic Surgery. Ann Surg. déc 2016;264(6):949­58.

[77] Othman MO et al. Introduction and practical approach to exocrine pancreatic insufficiency for the practicing clinician. Int J Clin Pract.2018;72(2):e13066.

[78] Belyaev O et al. Early and late post-operative changes in the quality of life after pancreatic surgery. Langenbecks Arch Surg. avr 2013;398(4):547­55.

[79] Phillips ME et al. Consensus for the management of pancreatic exocrine insuf­ficiency: UK practical guidelines. BMJ Open Gastroenterol. juin 2021;8(1):e000643.

[80] Beger HG et al. New Onset of Diabetes and Pancreatic Exocrine Insufficiency After Pancreaticoduodenectomy for Benign and Malignant Tumors: A Systematic Review and Meta­analysis of Long-­term Results.Ann Surg. févr 2018;267(2):259­70.

[81] Tseng DSJ et al. Pancreatic Exocrine Insufficiency in Patients With Pancreaticor Periampullary Cancer: A Systematic Review. Pancreas. mars 2016;45(3):325­30.

[82] Bartel MJ et al. Pancreatic exocrine insufficiency in pancreatic cancer: A review of the literature. Dig Liver Dis. 1 déc 2015;47(12):1013­20.

[83] Roeyen G et al. The impact of pancreaticoduodenectomy on endocrine and exo­crine pancreatic function: A prospective cohort study based on pre­ and post opera­tive function tests. Pancreatology. 1nov 2017;17(6):974­82.

[84] Shah KP et al. Long­-Term Assessment of Pancreatic Function After Pancreatec­tomy for Cystic Neoplasms. J Surg Res. mars 2020;247:547­55.

[85] Pezzilli R et al. Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer. Cancers. févr 2020;12(2):275.

[86] Löhr JM et al. UEG evidence-­based guidelines for the diagnosis and therapy ofchronic pancreatitis (HaPanEU). United Eur GastroenterolJ. mars 2017;5(2):153­99.

[87] Lv X et al. Impact of diabetes mellituson clinical outcomes of pancreatic can­cer after surgical resection: A systematic review and meta­-analysis. PloS One. 2017; 12(2):e0171370.

[88] Stoop TF et al. Total pancreatectomy as an alternative to high­risk pancreato­jejunostomy after pancreatoduodenectomy: a propensity score analysis on surgical outcome and quality of life. HPB. 1 janv 2022;S1365­182X(21)01744­5.

[89] Epelboym I et al. Quality of life in patients after total pancreatectomy is compa­rable with quality of life in patients who undergo a partial pancreatic resection. J Surg Res. mars 2014;187(1):189­96.

Auteurs : Renato Micelli Lupinacci (Boulogne-Billancourt), Sébastien Gaujoux (Paris). Rédaction : Renato Micelli Lupinacci. Liens d’intérêts : R.M Lupinacci : Viatris, S Gaujoux : Mayoli, Ipsen, Novartis. Directrice de Clientèle : Noëlle Croisat, Éditions John Libbey Eurotext, 07 63 59 03 68, noelle.croisat@jle.com. Chef de projet : Valérie Toulgoat, valerie.toulgoat@jle.com. Conception graphique : Stéphane Bouchard. Crédits photo : ©AdobeStock.com. Document réservé à l’usage exclusif du corps médical. Dépôt légal : © John Libbey 2022. La publication de ce contenu est effectuée sous la seule responsabilité de l’éditeur et de l’auteur. Ce document est diffusé en tant que service d’information aux professionnels de santé par les Laboratoires Viatris.

Avec le soutien institutionnel de